These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 36295635)

  • 1. An Update on the Current and Emerging Use of Thiazolidinediones for Type 2 Diabetes.
    Giglio RV; Papanas N; Rizvi AA; Ciaccio M; Patti AM; Ilias I; Pantea Stoian A; Sahebkar A; Janez A; Rizzo M
    Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
    Taylor C; Hobbs FD
    Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
    Simó R; Rodriguez A; Caveda E
    Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The "glitazones": rosiglitazone and pioglitazone.
    Papoushek C
    J Obstet Gynaecol Can; 2003 Oct; 25(10):853-7. PubMed ID: 14532954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
    Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
    Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thiazolidinediones: the Forgotten Diabetes Medications.
    Lebovitz HE
    Curr Diab Rep; 2019 Nov; 19(12):151. PubMed ID: 31776781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
    Defronzo RA; Mehta RJ; Schnure JJ
    Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety.
    Leonard CE; Brensinger CM; Dawwas GK; Deo R; Bilker WB; Soprano SE; Dhopeshwarkar N; Flory JH; Bloomgarden ZT; Gagne JJ; Aquilante CL; Kimmel SE; Hennessy S
    Cardiovasc Diabetol; 2020 Feb; 19(1):25. PubMed ID: 32098624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rational drug design and PPAR agonists.
    Perfetti R; D'Amico E
    Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
    Zinn A; Felson S; Fisher E; Schwartzbard A
    Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity with thiazolidinediones: is it a class effect?
    Scheen AJ
    Drug Saf; 2001; 24(12):873-88. PubMed ID: 11735645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
    Consoli A; Formoso G
    Diabetes Obes Metab; 2013 Nov; 15(11):967-77. PubMed ID: 23522285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
    Barnett AH
    Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of thiazolidinediones.
    Tolman KG
    Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosiglitazone and pioglitazone in the treatment of diabetes mellitus.
    Odom J; Williamson B; Carter L
    Am J Health Syst Pharm; 2008 Oct; 65(19):1846-50. PubMed ID: 18796427
    [No Abstract]   [Full Text] [Related]  

  • 18. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
    Krentz A
    Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
    Diamant M; Heine RJ
    Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.